Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis treatments. Basel-based Novartis had previously acquired the rights to Ofatumumab for oncology indications, but it is currently being developed for relapsing remitting multiple sclerosis and other auto-immune conditions.

Click here to read original article